vs
Side-by-side financial comparison of FENNEC PHARMACEUTICALS INC. (FENC) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $12.1M, roughly 1.1× TRANSCONTINENTAL REALTY INVESTORS INC). TRANSCONTINENTAL REALTY INVESTORS INC runs the higher net margin — 68.8% vs -34.7%, a 103.5% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 2.3%). Over the past eight quarters, TRANSCONTINENTAL REALTY INVESTORS INC's revenue compounded faster (0.7% CAGR vs -26.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.
FENC vs TCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $12.1M |
| Net Profit | $-4.8M | $8.3M |
| Gross Margin | — | — |
| Operating Margin | -18.5% | -28.9% |
| Net Margin | -34.7% | 68.8% |
| Revenue YoY | 73.8% | 2.3% |
| Net Profit YoY | -141.1% | 7577.8% |
| EPS (diluted) | $-0.17 | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $12.1M | ||
| Q3 25 | $12.5M | $12.8M | ||
| Q2 25 | $9.7M | $12.2M | ||
| Q1 25 | $8.8M | $12.0M | ||
| Q4 24 | $7.9M | $11.8M | ||
| Q3 24 | $7.0M | $11.6M | ||
| Q2 24 | $7.3M | $11.8M | ||
| Q1 24 | $25.4M | $11.9M |
| Q4 25 | $-4.8M | $8.3M | ||
| Q3 25 | $-638.0K | $724.0K | ||
| Q2 25 | $-3.2M | $169.0K | ||
| Q1 25 | $-1.2M | $4.6M | ||
| Q4 24 | $-2.0M | $108.0K | ||
| Q3 24 | $-5.7M | $1.7M | ||
| Q2 24 | $-5.6M | $1.5M | ||
| Q1 24 | $12.8M | $2.5M |
| Q4 25 | -18.5% | -28.9% | ||
| Q3 25 | -1.5% | -10.9% | ||
| Q2 25 | -28.3% | -6.8% | ||
| Q1 25 | -9.2% | -5.3% | ||
| Q4 24 | -11.8% | -14.3% | ||
| Q3 24 | -74.6% | -14.4% | ||
| Q2 24 | -69.4% | -9.2% | ||
| Q1 24 | 54.2% | -11.2% |
| Q4 25 | -34.7% | 68.8% | ||
| Q3 25 | -5.1% | 5.6% | ||
| Q2 25 | -32.7% | 1.4% | ||
| Q1 25 | -13.3% | 38.5% | ||
| Q4 24 | -25.0% | 0.9% | ||
| Q3 24 | -82.2% | 14.7% | ||
| Q2 24 | -76.5% | 12.7% | ||
| Q1 24 | 50.6% | 21.4% |
| Q4 25 | $-0.17 | $0.97 | ||
| Q3 25 | $-0.02 | $0.08 | ||
| Q2 25 | $-0.11 | $0.02 | ||
| Q1 25 | $-0.04 | $0.53 | ||
| Q4 24 | $-0.02 | $0.01 | ||
| Q3 24 | $-0.21 | $0.20 | ||
| Q2 24 | $-0.20 | $0.17 | ||
| Q1 24 | $0.41 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.8M | $89.0M |
| Total DebtLower is stronger | — | $210.8M |
| Stockholders' EquityBook value | $35.5M | $846.7M |
| Total Assets | $70.6M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.8M | $89.0M | ||
| Q3 25 | $21.9M | $82.7M | ||
| Q2 25 | $18.7M | $73.5M | ||
| Q1 25 | $22.7M | $88.6M | ||
| Q4 24 | $26.6M | $99.7M | ||
| Q3 24 | $40.3M | $131.6M | ||
| Q2 24 | $43.1M | $127.5M | ||
| Q1 24 | $51.2M | $130.8M |
| Q4 25 | — | $210.8M | ||
| Q3 25 | $19.4M | $223.5M | ||
| Q2 25 | $19.4M | $212.4M | ||
| Q1 25 | $19.4M | $198.2M | ||
| Q4 24 | $19.3M | $181.9M | ||
| Q3 24 | $32.1M | $180.3M | ||
| Q2 24 | $31.8M | $177.4M | ||
| Q1 24 | $31.3M | $178.3M |
| Q4 25 | $35.5M | $846.7M | ||
| Q3 25 | $-4.5M | $838.4M | ||
| Q2 25 | $-7.5M | $837.7M | ||
| Q1 25 | $-5.9M | $837.3M | ||
| Q4 24 | $-5.9M | $832.3M | ||
| Q3 24 | $-5.2M | $832.2M | ||
| Q2 24 | $-1.4M | $830.4M | ||
| Q1 24 | $3.0M | $828.9M |
| Q4 25 | $70.6M | $1.1B | ||
| Q3 25 | $49.3M | $1.1B | ||
| Q2 25 | $44.9M | $1.1B | ||
| Q1 25 | $46.4M | $1.1B | ||
| Q4 24 | $44.9M | $1.1B | ||
| Q3 24 | $58.9M | $1.1B | ||
| Q2 24 | $63.2M | $1.0B | ||
| Q1 24 | $69.2M | $1.0B |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | 10.40× | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $-2.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | $-2.9M | ||
| Q3 25 | $1.5M | $8.2M | ||
| Q2 25 | $-3.7M | $-2.9M | ||
| Q1 25 | $-4.3M | $-7.4M | ||
| Q4 24 | $-1.5M | $1.3M | ||
| Q3 24 | $-2.2M | $13.7M | ||
| Q2 24 | $-8.4M | $-511.0K | ||
| Q1 24 | $39.0M | $3.9M |
| Q4 25 | — | -0.35× | ||
| Q3 25 | — | 11.28× | ||
| Q2 25 | — | -17.24× | ||
| Q1 25 | — | -1.61× | ||
| Q4 24 | — | 12.13× | ||
| Q3 24 | — | 8.03× | ||
| Q2 24 | — | -0.34× | ||
| Q1 24 | 3.04× | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
